Benzinga | Sep 8, 2020 12:36PM EDT

BTIG Downgrades Corbus Pharmaceuticals to Neutral

BTIG analyst Dae Gon Ha downgrades Corbus Pharmaceuticals (NASDAQ:CRBP) from Buy to Neutral.